• Product nameAnti-Vinculin antibody
    See all Vinculin primary antibodies
  • Description
    Rabbit polyclonal to Vinculin
  • Tested applicationsSuitable for: IHC-P, ELISA, WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic non-phosphopeptide (Human) from around the phosphorylation site of tyrosine 821 (SGYPRI)

  • Positive control
    • Human breast carcinoma tissue



Our Abpromise guarantee covers the use of ab61186 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/50 - 1/100.
ELISA 1/10000.
WB 1/500 - 1/1000.
ICC/IF 1/100 - 1/500.


  • FunctionActin filament (F-actin)-binding protein involved in cell-matrix adhesion and cell-cell adhesion. Regulates cell-surface E-cadherin expression and potentiates mechanosensing by the E-cadherin complex. May also play important roles in cell morphology and locomotion.
  • Tissue specificityMetavinculin is muscle-specific.
  • Involvement in diseaseDefects in VCL are the cause of cardiomyopathy dilated type 1W (CMD1W) [MIM:611407]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
    Defects in VCL are the cause of cardiomyopathy familial hypertrophic type 15 (CMH15) [MIM:613255]. It is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
  • Sequence similaritiesBelongs to the vinculin/alpha-catenin family.
  • DomainExists in at least two conformations. When in the closed, 'inactive' conformation, extensive interactions between the head and tail domains prevent detectable binding to most of its ligands. It takes on an 'active' conformation after cooperative and simultaneous binding of two different ligands. This activation involves displacement of the head-tail interactions and leads to a significant accumulation of ternary complexes. The active form then binds a number of proteins that have both signaling and structural roles that are essential for cell adhesion.
    The N-terminal globular head (Vh) comprises of subdomains D1-D4. The C-terminal tail (Vt) binds F-actin and cross-links actin filaments into bundles. An intramolecular interaction between Vh and Vt masks the F-actin-binding domain located in Vt. The binding of talin and alpha-actinin to the D1 subdomain of vinculin induces a helical bundle conversion of this subdomain, leading to the disruption of the intramolecular interaction and the exposure of the cryptic F-actin-binding domain of Vt. Vt inhibits actin filament barbed end elongation without affecting the critical concentration of actin assembly.
  • Post-translational
    Phosphorylated; on serines, threonines and tyrosines. Phosphorylation on Tyr-1133 in activated platelets affects head-tail interactions and cell spreading but has no effect on actin binding nor on localization to focal adhesion plaques.
    Aceylated; mainly by myristic acid but also small amount of palmitic acid.
  • Cellular localizationCytoplasm > cytoskeleton. Cell junction > adherens junction. Cell membrane. Cytoplasmic face of adhesion plaques. Recruitment to cell-cell junctions occurs in a myosin II-dependent manner. Interaction with CTNNB1 is necessary for its localization to the cell-cell junctions.
  • Information by UniProt
  • Database links
  • Alternative names
    • CMD1W antibody
    • CMH15 antibody
    • Epididymis luminal protein 114 antibody
    • HEL114 antibody
    • Metavinculin antibody
    • MV antibody
    • MVCL antibody
    • OTTHUMP00000019861 antibody
    • OTTHUMP00000019862 antibody
    • VCL antibody
    • VINC antibody
    • VINC_HUMAN antibody
    • Vinculin antibody
    see all

Anti-Vinculin antibody images

  • Immunohistochemical analysis of paraffin embedded human breast carcinoma tissue using ab61186 at 1/50 dilution. Samples were treated -/+ immunising peptide.
  • All lanes : Anti-Vinculin antibody (ab61186)

    Lane 1 : Hela, treated with forskolin 40nM 30'
    Lane 2 : Synthesized Peptide
  • ab61186 staining A549 cells, image on right treated with synthesized peptide.

References for Anti-Vinculin antibody (ab61186)

This product has been referenced in:
  • Baeyens N  et al. Identification and functional implication of a Rho kinase-dependent moesin-EBP50 interaction in noradrenaline-stimulated artery. Am J Physiol Cell Physiol 299:C1530-40 (2010). WB ; Rat . Read more (PubMed: 20926777) »

See 1 Publication for this product

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Mouse Cell (Mouse Embryonic Fibroblast (MEF))
Specification Mouse Embryonic Fibroblast (MEF)
Fixative Paraformaldehyde
Permeabilization Yes - triton

Abcam user community

Verified customer

Submitted Nov 16 2011

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa cell line ( cervical cancer))
Specification HeLa cell line ( cervical cancer)
Fixative Paraformaldehyde
Permeabilization Yes - triton

Abcam user community

Verified customer

Submitted Nov 16 2011

Thank you for your enquiry which has been forwarded to the scientific support team. I am sorry we do not provide larger vial sizes. We can offer a discount if you purchase 5 vials or more on one order (of the same product, or different products). I...

Read More

Thank you for contacting us and for reporting the problem you experienced with the antibody ab61186. I am sorry that the product you received did not perform as stated expected. We have recently updated the datasheet and the antibody should ind...

Read More
Application Immunocytochemistry/ Immunofluorescence
Sample Rat Cell (Neonatal Ventricular Myocyte)
Specification Neonatal Ventricular Myocyte
Fixative Paraformaldehyde
Permeabilization Yes - Triton X 100
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 1% · Temperature: 25°C

Dr. Natasha Mehta

Verified customer

Submitted May 18 2009